Magnesium (Mg)-based alloys have gained significant attention as next-generation biodegradable biomaterials due to their bone-mimetic mechanical properties (elastic modulus: 35–45 GPa), biocompatibility, and ability to degrade in vivo without toxic byproducts. This review systematically evaluates recent advances in Mg-based alloys for biomedical applications, focusing on orthopedic implants, cardiovascular stents, and drug delivery systems, while identifying current challenges and future research directions. We conducted a comprehensive literature analysis of peer-reviewed studies (2019–2024) examining Mg alloy development, surface modification techniques, in vitro/in vivo performance, and clinical trial outcomes. Key findings include: (1) Alloying innovations, particularly with rare-earth elements (e.g., in WE43) and nutrient elements (Zn, Ca), have yielded alloys with bone-mimetic mechanical properties (elastic modulus: 35–45 GPa; compressive yield strength: 150–250 MPa) and decelerated degradation rates via grain refinement and secondary phase formation; (2) Surface-modified Mg stents show improved endothelialization with 30–50 % reduced restenosis rates (3) Structurally engineered Mg-based scaffolds (e.g., via additive manufacturing); enable topological control over degradation through tailored porosity; (4) Drug-eluting Mg carriers achieve sustained release kinetics, leveraging degradation to simultaneously promote tissue regeneration and deliver therapeutics. However, rapid degradation (0.2–0.5 mm/year in physiological conditions) and hydrogen gas evolution remain critical challenges. Mg-based alloys show transformative potential for temporary medical implants. Future research should focus on: (1) advanced alloy design with rare-earth elements, (2) smart coating technologies, and (3) standardized long-term biocompatibility assessments to facilitate clinical translation.

Precise deposition of nanofibers is still an important issue in the applications of electrospinning (e-spinning), especially in rapid hemostasis of organs such as the liver, lung, and kidney. In this study, we propose an electric field-modified e-spinning technique with a metal cone attached to the spinning nozzle to realize controllable precise deposition of fibers. The deposition range of the e-spun fibers is tunable by changing the size of the metal cone, and the mechanism is attributed the focused electric field verified by theoretical simulations. This electric field-modified e-spinning method was further used to in situ precisely deposit medical glue N-octyl-2-cyanoacrylate (NOCA) fibers onto the resection site of rat liver to realize rapid hemostasis within 10 s. Postoperative pathological results indicate that less inflammatory response and tissue adhesion are observed in this electric field-modified e-spinning group compared with that of traditional airflow-assisted group. This technique combined with our designed handheld e-spinning device could be used in emergency medical treatment, clinics, field survival, and home care for its portability and precise deposition characteristics.

Situs inversus totalis (SIT) is a rare congenital anatomical variation. However, patients with SIT combined with cancer are rare and these patients with two types of lung cancer have not been reported. We report here a case of combined lung adenocarcinoma and solitary fibrous tumor of the pleura with SIT and discuss its clinicopathological features and outcomes. A 68-year-old asymptomatic woman was referred to the Affiliated Hospital of Qingdao University because of an abnormal shadow on chest radiography. Computed tomography showed SIT and an irregularly shaped nodule (measuring 38 × 27 mm in diameter) in the pleural area of the left lower lobe and a 5-mm nodule in the dorsal segment of the lower lobe of the left lung. Surgery was then performed. For such patients, we should eliminate anxiety in patients, perform regular reexaminations, focus on the individual features of these patients, and avoid misdiagnosis because of habitual thinking. At the same time, the lymph nodes should be completely removed and different parts of the tumor with different properties should be treated differently according to the situation.

Constitutional indocyanine green (ICG) excretory defect is rare. However, ICG excretory defect concomitant with hepatocellular carcinoma (HCC) is extremely rare, and only six reports of hepatectomy in patients with constitutional ICG excretory defect have been published in the English language literature through 2020. In this study, we report a case of combined HCC and ICG excretory defect and discuss its clinicopathological features and outcomes. The case featured a 68-year-old man who was admitted to the hospital with a diagnosis of resectable HCC. The preoperative ICG retention rate at 15 minutes was 82.9%. Despite this finding, the Child–Pugh assessment and hepatobiliary-specific magnetic resonance imaging (MRI) did not reveal any abnormal findings. Therefore, we diagnosed the patient with constitutional ICG excretory defect and performed partial hepatectomy. For patients requiring hepatectomy, the indications and procedure for surgery should be considered. These should be based on liver function tests such as gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI.

Objective: To investigate the effects of fatigue on the survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Patients and Methods: A retrospective analysis of 182 cases of patients with advanced hepatocellular carcinoma treated with sorafenib in our hospital from October 1, 2008, to October 31, 2017, showed clinical and pathological data and follow-up results. The clinical and pathological data as well as follow-up results of 182 patients with advanced hepatocellular carcinoma treated with sorafenib in our hospital from October 1, 2008, to October 31, 2018, were retrospectively analyzed. All patients were treated for at least 3 months. Patients were divided into three groups: fatigue grade I (n=74), fatigue grade II (n=62), and fatigue grade III (n=46), according to National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 5.0. Survival analysis between groups was performed by the Kaplan Meier method (Log rank test), continuous variables were analyzed by t-test, and categorical variables were analyzed by chi-square test. Results: The overall survival (OS) of patients who were relieved of fatigue was 33.0 +/- 9.3 months, whereas the OS of patients who were not relieved of fatigue was 15.0 +/- 1.8 months (P<0.000). Furthermore, the time to progress (TTP) of patients who were relieved of fatigue by resting was 20.3 +/- 10.9 months compared to a TTP of 7.7 1.0 months in patients who were not relieved of fatigue (P<0.000). Conclusion: Patients, especially the elderly and infirm, were more susceptible to toxicity.